OraSure Technologies Company Profile (NASDAQ:OSUR)

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

OraSure Technologies, Inc. (NASDAQ:OSUR) announced its earnings results on Wednesday, May, 3rd. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.04. The firm had revenue of $32.55 million for the quarter, compared to the consensus estimate of $31.19 million. OraSure Technologies had a net margin of 22.57% and a return on equity of 16.06%. The firm's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.04 EPS. View OraSure Technologies' Earnings History.

OraSure Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for OraSure Technologies.

OraSure Technologies issued an update on its second quarter earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of $0.07-0.08 for the period, compared to the Thomson Reuters consensus estimate of $0.06. The company issued revenue guidance of $36.5-37.0 million, compared to the consensus revenue estimate of $33.86 million.

6 brokers have issued 12-month price objectives for OraSure Technologies' shares. Their predictions range from $8.00 to $19.00. On average, they anticipate OraSure Technologies' share price to reach $14.38 in the next year. View Analyst Ratings for OraSure Technologies.

Here are some recent quotes from research analysts about OraSure Technologies stock:

• 1. According to Zacks Investment Research, "OraSure Technologies, Inc. is the market leader for oral fluid diagnostics. The Company develops, manufactures, and markets medical devices and diagnostic products for use by insurance companies, public health agencies, clinical laboratories, physicians' offices, and workplace sites. " (5/6/2017)
• 2. BTIG Research analysts commented, "While we do not see any meaningful negatives for OSUR shares and see room for slight appreciation over time, we feel a lot of good news and higher expectations are now built into shares and would prefer a better entry point," analyst Karen Koski wrote in a note.Related Link: How The Zika Virus Spread While Congress With Out On RecessHowever, Koski acknowledged the company's new $18 million HCV test contract, improving operating margins, and a solid balance sheet. But, the analyst prefers to stay on sidelines due to the OraSure's "lumpy sales."Though OSUR has met or exceeded its sales guidance every quarter for the past several years, investors care most about HCV testing and DNAG sales, which can be lumpy," (9/19/2016)

Some companies that are related to OraSure Technologies include Haemonetics Corporation (HAE), Inogen (INGN), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), K2M Group Holdings (KTWO), Asante Solutions (PUMP), Cardiovascular Systems (CSII), Orthofix International N.V. (OFIX), Intersect ENT (XENT), AtriCure (ATRC), CryoLife (CRY), Meridian Bioscience (VIVO), Landauer (LDR), Consort Medical plc (CSRT), Antares Pharma (ATRS), Exactech (EXAC) and STAAR Surgical Company (STAA).

OraSure Technologies' management team includes the folowing people:

• Stephen S. Tang Ph.D., Chairman of the Board
• Douglas A. Michels, President, Chief Executive Officer, Director
• Ronald H. Spair, Chief Financial Officer, Chief Operating Officer, Director
• Anthony II Zezzo II, Executive Vice President - Marketing and Sales
• Mark L. Kuna, Senior Vice President - Finance, Controller, Assistant Secretary
• Michael Reed Ph.D., Senior Vice President - Research and Development, Chief Scientific Officer
• Jack E. Jerrett, Senior Vice President, General Counsel, Secretary
• Mara Glickman Aspinall, Director
• Eamonn P. Hobbs, Director
• Michael Celano, Independent Director

OraSure Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (3.20%), Fisher Asset Management LLC (1.18%), Russell Investments Group Ltd. (0.86%), Bank of Montreal Can (0.25%), Adams Diversified Equity Fund Inc. (0.13%) and Shell Asset Management Co. (0.10%). Company insiders that own OraSure Technologies stock include Anthony Zezzo II, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Mark L Kuna, Michael Celano, Ronald H Spair, Ronny B Lancaster and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies.

OraSure Technologies' stock was sold by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Adams Diversified Equity Fund Inc. and Strs Ohio. Company insiders that have sold OraSure Technologies stock in the last year include Anthony Zezzo II, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Mark L Kuna, Michael Celano, Ronald H Spair, Ronny B Lancaster and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies.

OraSure Technologies' stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., Fisher Asset Management LLC, Bank of Montreal Can, Capstone Asset Management Co., Eqis Capital Management Inc., NN Investment Partners Holdings N.V. and Hartford Investment Management Co.. View Insider Buying and Selling for OraSure Technologies.

Shares of OraSure Technologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OraSure Technologies stock can currently be purchased for approximately $18.25.